P300 Sequence Effects, Probability, and Interstimulus Interval

J. Polich,T. Bondurant

DOI: https://doi.org/10.1016/S0031-9384(96)00564-1

1997-06-01

Abstract:

What problem does this paper attempt to address?

Consensus statement on non-cancer-related risk factors for development of secondary lymphedema

Nicole L Stout,Marize Ibrahim,Jane Armer,Mary Vargo,Julia Rodrick,Jeanne Nourse,Brandy McKeown,Jessica C Griffin,Melissa B Aldrich

DOI: https://doi.org/10.1007/s12032-024-02457-8

2024-10-14

Abstract:Non-cancer-related risk factors for secondary lymphedema were defined across four categories: co-morbidity, social determinants of health, behavioral factors, and environmental effectors. Based on rapid reviews of the literature and presentations at the ACS/LANA Lymphedema Summit, this working group categorized these risk factors according to the strength of evidence. Consensus agreement on level of evidence was achieved through one face-to-face working session and three follow-up virtual meetings. Findings elucidate strong evidence for co-morbidities, such as cardio/metabolic and vascular factors contributing to the risk for lymphedema. Evidence is low-to-moderate for social and behavioral factors and is lacking for environmental factors. Panel recommendations suggest a tailored approach to prospective surveillance when monitoring for secondary lymphedema that includes social determinants of health considering the growing awareness and evidence of these factors' influence on cancer and cancer-related morbidity.
Cancer-Related Lymphedema Risk Factors, Diagnosis, Treatment, and Impact: A Review

Electra D. Paskett,Julie A. Dean,Jill M. Oliveri,J. Phil Harrop

DOI: https://doi.org/10.1200/jco.2012.41.8574

IF: 45.3

2012-10-20

Journal of Clinical Oncology

Abstract:Purpose Cancer-related lymphedema (LE) is an incurable condition associated with lymph-involved cancer treatments and is an increasing health, quality of life (QOL), and cost burden on a growing cancer survivor population. This review examines the evidence for causes, risk, prevention, diagnosis, treatment, and impact of this largely unexamined survivorship concern. Methods PubMed and Medline were searched for cancer-related LE literature published since 1990 in English. The resulting references (N = 726) were evaluated for strength of design, methods, sample size, and recent publication and sorted into categories (ie, causes/prevention, diagnosis, treatment, and QOL). Sixty studies were included. Results Exercise and physical activity and sentinel lymph node biopsy reduce risk, and overweight and obesity increase risk. Evidence that physiotherapy reduces risk and that lymph node status and number of malignant nodes increase risk is less strong. Perometry and bioimpedence emerged as attractive diagnostic technologies, replacing the use of water displacement in clinical practice. Swelling can also be assessed by measuring arm circumference and relying on self-report. Symptoms can be managed, not cured, with complex physical therapy, low-level laser therapy, pharmacotherapy, and surgery. Sequelae of LE negatively affect physical and mental QOL and range in severity. However, the majority of reviewed studies involved patients with breast cancer; therefore, results may not be applicable to all cancers. Conclusion Research into causes, prevention, and effect on QOL of LE and information on LE in cancers other than breast is needed. Consensus on definitions and measurement, increased patient and provider awareness of signs and symptoms, and proper and prompt treatment/access, including psychosocial support, are needed to better understand, prevent, and treat LE.

oncology
Breast cancer‐related lymphedema: A comprehensive analysis of risk factors

Charalampos Siotos,Sydney H. Arnold,Michelle Seu,Lilia Lunt,Jennifer Ferraro,Daniel Najafali,George Damoulakis,Joshua Vorstenbosch,Babak J. Mehrara,Anuja K. Antony,Deana S. Shenaq,George Kokosis

DOI: https://doi.org/10.1002/jso.27841

2024-08-29

Journal of Surgical Oncology

Abstract:Background Breast cancer‐related lymphedema is a devastating condition that negatively affects the quality of life of breast cancer survivors. We sought to identify risk factors that predicted the timing and development of lymphedema. Methods Women with breast cancer that underwent sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND) at our institution between 2007 and 2022 were identified and sociodemographic and clinical information was extracted. We used logistic regression analysis to identify risk factors for lymphedema and performed cox‐regression analysis to predict the timing of lymphedema presentation after surgery. Results We identified 1,223 patients, of which 161 (13.2%) developed lymphedema within 1.8 (mean, SD = 2.5) years postoperatively. Patients with SLNB had significantly lower odds for lymphedema development (vs. ALND, OR = 0.29 [0.14–0.57]). Patients between 40 and 49 years of age, and 50‐59 (vs. <40 years, OR = 2.14 [1.00–4.60]; OR = 2.42, [1.13–5.16] respectively), African American patients (vs. Caucasian, OR = 1.86 [1.12–3.09]), patients with stage II, III, and IV disease (vs. stage 0, OR = 3.75 [1.36–10.33]; OR = 6.62 [2.14–20.51]; OR = 9.36 [2.94–29.81]), and patients with Medicaid (vs. private insurance, OR = 3.56 [1.73–7.28]) had higher rates of lymphedema. Cox‐regression analysis showed that African American (HR = 1.71 [1.08–2.70]), higher BMI (HR = 1.03 [1.00–1.06]), higher stage (stage II, HR = 2.22 [1.05–7.09]; stage III, HR = 5.26 [1.86–14.88]; stage IV, HR = 6.13 [2.12–17.75]), and Medicaid patients (HR = 2.15 [1.12–3.80]) had higher hazards for lymphedema. Patients with SLNB had lower hazards for lymphedema (HR = 0.43 [0.87–2.11]). Conclusion Lymphedema has identifiable risk factors that can reliably be used to predict the chances of lymphedema development and enable clinicians to educate patients better and formulate treatment plans accordingly. Level of Evidence III (Retrospective study).

oncology,surgery
Prevalence and incidence of cancer related lymphedema in low and middle-income countries: a systematic review and meta-analysis

Eric Torgbenu,Tim Luckett,Mark A Buhagiar,Sungwon Chang,Jane L Phillips

DOI: https://doi.org/10.1186/s12885-020-07079-7

IF: 4.638

2020-06-29

BMC Cancer

Abstract:Background: Little is known about the prevalence and incidence in low and middle-income countries (LMICs) of secondary lymphedema due to cancer. The purpose of the study is to estimate the prevalence and incidence in LMICs of secondary lymphedema related to cancer and/or its treatment(s) and identify risk factors. Method: A systematic review and meta-analysis was conducted. Medline, EMBASE and CINAHL were searched in June 2019 for peer-reviewed articles that assessed prevalence and/or incidence of cancer-related lymphedema in LMICs. Risk of bias was assessed using the Joanna Briggs Institute Critical Appraisal Checklist for Prevalence Studies. Estimates of pooled prevalence and incidence estimates were calculated with 95% confidence intervals (CI), with sub-group analyses grouping studies according to: country of origin, study design, risk of bias, setting, treatment, and lymphedema site and measurement. Heterogeneity was measured using X2 and I2, with interpretation guided by the Cochrane Handbook for Systematic Reviews. Results: Of 8766 articles, 36 were included. Most reported on arm lymphedema secondary to breast cancer treatment (n = 31), with the remainder reporting on leg lymphedema following gynecological cancer treatment (n = 5). Arm lymphedema was mostly measured by arm circumference (n = 16/31 studies), and leg lymphedema through self-report (n = 3/5 studies). Eight studies used more than one lymphedema measurement. Only two studies that measured prevalence of leg lymphedema could be included in a meta-analysis (pooled prevalence =10.0, 95% CI 7.0-13.0, I2 = 0%). The pooled prevalence of arm lymphedema was 27%, with considerable heterogeneity (95% CI 20.0-34.0, I2 = 94.69%, n = 13 studies). The pooled incidence for arm lymphedema was 21%, also with considerable heterogeneity (95% CI 15.0-26.0, I2 = 95.29%, n = 11 studies). There was evidence that higher body mass index (> 25) was associated with increased risk of arm lymphedema (OR: 1.98, 95% CI 1.45-2.70, I2 = 84.0%, P < 0.0001, n = 4 studies). Conclusion: Better understanding the factors that contribute to variability in cancer-related arm lymphedema in LMICs is an important first step to developing targeted interventions to improve quality of life. Standardising measurement of lymphedema globally and better reporting would enable comparison within the context of information about cancer treatments and lymphedema care.
Policy Forum : Confusion Worse Confounded — The Supreme Court ’ s GAAR Decisions

B. Arnold

Abstract:This article analyzes the Supreme Court of Canada’s decisions in Canada Trustco v. The Queen and Mathew v. The Queen, the first cases heard by the court involving the application of the general anti-avoidance rule (GAAR). The article begins with a review of the case law, followed by an examination of the Supreme Court’s statements with respect to statutory interpretation in general. The heart of the article deals with the court’s interpretation of the GAAR and its application in the two cases, and concludes with some speculation about the implications of the decisions for future cases
Chemical reaction kinetics is back: Attempts to deal with complexity in biology: Developing a quantitative molecular view to understanding life

P. Schuster

DOI: https://doi.org/10.1002/cplx.20056

2004-09-01

Abstract:N ew strategies to handle complexity in biology have been and are developed under the catch phrase “systems biology.” What stands in the core of this recent field of research is the concept to understand and model cells and organisms as high-dimensional dynamical systems and to determine the necessary input parameters by experiment. Regulation of gene activities and metabolic functions are encapsulated in differential equations that have their origin in chemical reaction kinetics. Needless to say, this approach has to envisage enormous complexity. On the other hand, solution of large numbers of kinetic equations, up to one thousand and more commonly rather stiff equations, is routine in combustion chemistry and flame modeling. What’s new, however, is the fact that cellular reaction networks have a number of unique properties unknown in physics and chemistry. They are not only selfregulated but they are also capable of reproduction, they are robust and don’t change their state under often not so small changes in the environment, and they can tolerate loss of one or the other constituent without loosing function. Both the experimental [1] and the computational approach to systems biology [2, 3] have made substantial progress within the last few years. Somehow, the mathematical analysis of the basic properties of genetic and metabolic networks is lagging behind [4, 5]. Despite undoubted success [6], many fundamental questions are still unanswered. Over many decades, molecular biology has been extraordinarily successful in applying a qualitative molecular view to understanding life. This qualitative image of nature is based on yes-or-no answers rather than the conventional quantitative
Risk Factors for Breast Cancer-Related Lymphedema: An Umbrella Review

Aomei Shen,Wanmin Qiang,Liyuan Zhang,Jingru Bian,Fei Zhu,Zijuan Zhang,Qian Lu

DOI: https://doi.org/10.1245/s10434-023-14277-7

Abstract:Background: Identification of risk factors facilitates the prevention of breast cancer-related lymphedema (BCRL). Several published systematic reviews have already addressed the risk factors for BCRL. This study aimed to systematically identify potential risk factors for BCRL and evaluate the quality of evidence. Methods: The study followed methodologic guidance from the Joanna Briggs Institute, and the Cochrane Handbook. The following electronic databases were systematically searched from inception to 15 November 2022: PubMed, Embase, CINAHL, Web of Science, Scopus, CNKI, SinoMed, Wanfang, JBI Database, Cochrane Database, ProQuest, and PROSPERO. Two authors independently screened studies, extracted data, and assessed methodologic quality using AMSTAR2, risk of bias using ROBIS, and evidence quality using GRADE. The study evaluated overlap, assessed the small-study effect, and calculated the I2 statistic and Egger's P value as needed. Results: The study included 14 publications comprising 10 meta-analyses and 4 systematic reviews. The authors identified 39 factors and 30 unique meta-analyses. In the study, 13 innate personal trait-related risk factors, such as higher body mass index (BMI) and axillary lymph nodes dissection, showed statistically significant associations with BCRL incidence. Breast reconstruction was found to be a protective factor. The methodologic quality was low or critically low. The majority of the systematic reviews and/or meta-analyses were rated as having a high risk of bias. Evidence quality was low for 22 associations and moderate for 8 associations. Conclusions: The currently identified risk factors for BCRL all are innate personal trait-related factors. Future well-designed studies and robust meta-analyses are needed to explore potential associations between behavioral-, interpersonal-, and environmental-related factors and BCRL, as well as the role of genetic variations and pathophysiologic factors.
Risk Factors Associated with Breast Cancer-Related Lymphedema: A Systematic Review and Meta-Analysis

DOI: https://doi.org/10.33140/jgrm.06.03.04

2022-06-01

Journal of Gynecology & Reproductive Medicine

Abstract:Background: Lymphedema is a chronic, progressive condition that commonly occurs after treatment for breast cancer. Therefore, this study aimed to assess the incidence and risk factors of breast cancer-related lymphedema (BCRL). Methods: PubMed, Web of Science, Embase, MEDLINE, CNKl, Wang Fang DATA, Vip Database, and SinoMed were searched from January 2000 to January 2022. Risk of bias was assessed using the Newcastle-Ottawa Scale. Estimates of pooled incidence and risk factors estimates were calculated with 95% confidence intervals (CI), with sub-group analyses according to country, study design, population characteristics, the definition of lymphedema, and risk of bias. Heterogeneity was measured using I2 and publication bias was analyzed by funnel plot. Results: 34 studies comprising 23,988 participants were included in this study, with a follow-up period ranging from 1 to 10.2 years. The estimated pooled cumulative incidence at 1,2,3,5 years post-operative for patients respectively was 20%, 17%, 18% and 23%. Factors like: stage III cancer (RR: 1.34; 95% Cl: 1.17-1.52), age≥50 (RR: 1.47; 95% Cl: 1.23-1.76), BMI ≥25 (RR: 2.09; 95% Cl: 1.85-2.36), ALND (RR: 2.72; 95% Cl: 1.89-3.92), axillary radiotherapy (RR: 2.19; 95% Cl: 1.64-2.92), Neo-adjuvant chemotherapy (RR: 1.61; 95% Cl: 1.08-2.39), adjuvant taxane-based chemotherapy (RR: 1.65; 95% Cl: 1.25-2.19) and postoperative wound complications (RR: 1.66; 95% Cl: 1.13- 2.43) were significantly associated with BCRL. Conclusions: Our analyses suggest that BCRL risk is significantly associated with cancer stage, age, BMI, ALND, radiotherapy, chemotherapy, and postoperative wound complications.
The role of information sources and objective risk status on lymphedema risk-minimization behaviors in women recently diagnosed with breast cancer

Kerry A Sherman,Louise Koelmeyer

DOI: https://doi.org/10.1188/11.ONF.E27-E36

Abstract:Purpose/objectives: to assess the role of education sources and objective risk status on knowledge and practice of lymphedema risk-minimization behaviors among women recently diagnosed with breast cancer. Research approach: prospective survey. Setting: a hospital in Sydney, Australia. Participants: 106 women recently diagnosed with breast cancer at increased risk for developing lymphedema following lymph node dissection. Methodologic approach: a questionnaire administered at the time of surgery and three months after surgery measured demographics, lymphedema knowledge, lymphedema information sources used, and adherence to risk-minimization recommendations. Main research variables: lymphedema knowledge, source of information used, objective lymphedema risk, and adherence to risk-minimization behaviors. Findings: knowledge was high and increased over time. Lymphedema information from the clinic (e.g., brochures, nursing staff) was the most cited source. Adherence to recommendations was moderate; nonadherence was mostly for behaviors requiring regular enactment. Regression analysis revealed that only receipt of information from nursing staff and lymphedema knowledge three months after surgery were significant predictors of risk-minimization behaviors. Conclusions: exposing women to lymphedema risk information at the time of breast cancer diagnosis facilitates increased awareness and enactment of risk-minimization behaviors. Nursing staff play a key role in disseminating this information and in convincing women to perform the recommendations. Interpretation: provision of lymphedema education by breast clinic staff is critical to ensure that women realize the importance of early detection and treatment. Reminder booster sessions by nursing staff may be beneficial particularly for longer-term knowledge retention and adherence to recommended behaviors.
Risk factors of breast cancer-related lymphoedema: protocol of an umbrella review

Aomei Shen,Qian Lu,Liyuan Zhang,Jingru Bian,Fei Zhu,Zijuan Zhang,Wanmin Qiang

DOI: https://doi.org/10.1136/bmjopen-2022-070907

IF: 3.006

2023-04-12

BMJ Open

Abstract:Introduction: Breast cancer-related lymphoedema (BCRL) is a progressive and debilitating complication post-breast cancer treatment. Identifying potential risk factors facilitates the prevention and management of BCRL. Multiple systematic reviews have been conducted to address the variables correlated with the occurrence of BCRL. This study aims to identify and examine factors predicting the development of BCRL, to clarify the predicting mechanism of these factors, as well to determine the credibility of risk factors for BCRL. Methods and analysis: This umbrella review will be conducted with the methodological guidance of the Joanna Briggs Institute and the Cochrane handbook. A comprehensive systematic search will be performed in ten databases: PubMed, Embase, CINAHL, Web of Science, Scopus, CNKI, SinoMed, Wangfang database, the JBI Database of Systematic Reviews, Cochrane Database of Systematic Reviews. The search for unpublished studies will include ProQuest and the PROSPERO register. Reference lists will also be hand searched. Two reviewers will independently screen the studies, extract data and assess the methodological quality using the Methodological Quality of Systematic Reviews-2 and the Risk of Bias in Systematic Reviews. The degree of overlap between included reviews will be assessed by calculating the Corrected Covered Area. The credibility of the associations between risk factors and lymphoedema will be graded into four classes: convincing, highly suggestive, suggestive and weak, referring to the classification system of recent umbrella reviews. A descriptive, narrative synthesis and suggestions for clinical practice and future research will be made based on included systematic reviews, considering the quality of the evidence. Ethics and dissemination: Ethical approval is not required for this umbrella review. We will seek to submit the results for publication in a peer-reviewed journal or present it at conferences. Prospero registration number: CRD42022375710.
Advances in understanding and management of lymphoedema (cancer, primary)

Vaughan Keeley

DOI: https://doi.org/10.1097/SPC.0000000000000311

Abstract:Purpose of review: Despite being neglected both clinically and in research in the past, primary lymphoedema, and lymphoedema secondary to cancer treatment have been the subject of an increasing number of studies in recent years. This review will focus on new developments relevant to clinical practice. Recent findings: The main themes covered by the review include the incidence and prevalence of lymphoedema, early detection and intervention in cancer-related lymphoedema, risk reduction for the development of cancer-related lymphoedema, surgical treatment, palliative care for lymphoedema in advanced cancer and developments in the genetics of primary lymphoedema. Summary: Evidence suggests that lymphoedema is more common than has been previously recognized. It continues to be a significant problem for people following cancer treatment. Developments in the early detection and treatment of cancer-related lymphoedema should reduce the future impact for patients. Advice on how to reduce the risk of developing lymphoedema may need to be modified in light of recent research. New treatments such as surgical procedures are still in their infancy but the results seem encouraging for selected patients.
Psychosocial Impact of Living With Cancer-Related Lymphedema

Mei R. Fu,Yang Kang

DOI: https://doi.org/10.1016/j.soncn.2012.11.007

IF: 2.2

2013-02-01

Seminars in Oncology Nursing

Abstract:OBJECTIVES: To summarize the evidence of and identify factors influencing the psychosocial impact of lymphedema, as well as to discuss nursing strategies.DATA SOURCES: Peer-reviewed publications from 2004 to 2011 in 11 major medical indices.CONCLUSION: Poorer overall health-related quality of life was reported among cancer survivors with lymphedema. The consistent, detailed, and vivid descriptions from the qualitative studies suggest that cancer-related lymphedema exerts tremendous negative psychosocial impact, which quantitative studies failed to capture.IMPLICATIONS FOR NURSING PRACTICE: Nursing strategies include helping patients to build a routine for daily care, setting goals, exercise, positive self-talk, providing helpful resources, and organizing support groups. Professional organizations should devote resources to public education through television advertisement, public meetings, and online education.

nursing,oncology
Liposomal vincristine for the treatment of human acute lymphoblastic leukaemia in severe combined immunodeficient (SCID) mice.

J. Millar,B. Millar,R. Powles,J. Steele,R. Clutterbuck,P. Mitchell,G. Cox,E. Forssen,D. Catovsky

DOI: https://doi.org/10.1046/J.1365-2141.1998.00831.X

1998-08-01

British Journal of Haematology

Abstract:Non-obese diabetic NOD/SCID mice have been used to grow human leukaemia as a systemic disease. The animals were inoculated with leukaemic cells obtained from a 36-year-old male with early B-cell precursor acute lymphoblastic leukaemia and on day 15 were given the first of three weekly injections of 1 mg/kg vincristine or equimolar liposomal vincristine. The development of leukaemia in the mice was monitored by taking weekly blood samples and measuring the cell content by flow cytometry. The median time to 50% human cells in the peripheral blood of mice treated with free vincristine was 41 d from the start of treatment compared with 49 d for mice treated with liposomal vincristine (P < 0.01). The median day of death for mice treated with free vincristine was 47 d from the start of treatment and 57 d for mice receiving liposomal vincristine (P<0.01), thus providing a 21% increase in lifespan for animals treated with the liposomal preparation. There was slightly greater weight loss in mice treated with free vincristine than those given liposomal vincristine. Measurement of in vitro colony forming bone marrow progenitor cells in similarly treated, tumour-free mice, showed no difference in progenitor cell survival between mice that received either type of vincristine. We conclude that encapsulating vincristine in liposomes improves the therapeutic index of this drug measured in mice bearing human leukaemia. This may lead to use of the drug in conventional combination chemotherapy with greater safety or, in this setting, at higher dosage.
The Impact of Obesity on Success of Immediate Lymphatic Reconstruction for Prevention of Breast Cancer-Related Lymphedema

D'Arcy J Wainwright,Nicole K Le,Brielle Weinstein,William West,Tina Tavares,Nicholas J Panetta

DOI: https://doi.org/10.1097/SAP.0000000000003956

2024-06-01

Abstract:Background: Breast cancer-related lymphedema (BRCL) is a potential sequela of high-risk breast cancer treatment. Preventive treatment with immediate lymphatic reconstruction (ILR) at the time of axillary lymph node dissection (ALND) has emerged as the standard of care; however, there is relatively little known about factors that may contribute to procedural failure. Methods: A retrospectively maintained, institutional review board-approved study followed patients who underwent ILR at the time of ALND at our tertiary care center between May 2018 and May 2023. Patients who presented for at least one follow-up visit in our multidisciplinary lymphedema clinic met the criteria for inclusion. Patients who developed lymphedema despite ILR and potential contributing factors were further explored. Results: 349 patients underwent ILR at our institution between May 2018 and May 2023. 341 of these patients have presented for follow-up in our multidisciplinary lymphedema clinic. 32 (9.4%) patients developed lymphedema despite ILR. This cohort was significantly more likely to be obese (56% vs 35%, P = 0.04). Multivariate logistic regression demonstrates increased odds of procedural failure in patients with a body mass index (BMI) ≥30 kg/m2 (odds ratio 2.6 [1.2-5.5], P = 0.01). Conclusion: These data comment upon our institutions outcomes following ILR. Patients who develop lymphedema despite ILR tend to have a higher BMI, with a significantly increased risk in patients with a BMI of 30 or greater. Consideration of these data is critical for preprocedural counseling and may support a BMI cutoff when considering candidacy for ILR going forward, as well as when optimizing failures for secondary lymphedema procedures.
Factors associated with lymphedema self-management behaviours among breast cancer survivors: A cross-sectional study

Aomei Shen,Peipei Wu,Wanmin Qiang,Xin Fu,Fei Zhu,Lisha Pang,Fangfang Wang,Qian Lu

DOI: https://doi.org/10.1111/jocn.16833

Abstract:Aims and objectives: The purpose of this empirical study was to explore the current status and associated factors of lymphedema self-management behaviours among Chinese breast cancer survivors. Background: Breast cancer-related lymphedema is a lifetime concern for survivors and is currently incurable. Lifetime lymphedema self-management takes a significant role in preventing development and progression of lymphedema. Understanding influencing factors of lymphedema self-management behaviours can help to develop targeted intervention programs. Design: A multicentre cross-sectional study. Methods: From December 2021 to April 2022, a convenience sample of 586 participants were recruited at four tertiary hospitals in four cities in China. Self-reported questionnaires were used to measure socio-demographic characteristics, disease-and treatment-related characteristics, lymphedema self-management behaviours, lymphedema knowledge, illness perception, self-efficacy, self-regulation and social support. Descriptive analysis, bivariate analysis and hierarchical multiple regression were conducted. This study was registered at Chinese Clinical Trial Registry (ChiCTR2200057084), and was reported followed the STROBE checklist. Results: Breast cancer survivors reported moderate level of lymphedema self-management behaviours. Promotion of lymph reflux management was ranked the least performed self-management behaviours, while the affected limb protection management ranked the most. 36.2% of self-management behaviours was explained by exercise regularly, level of attention on lymphedema prevention, unclear about the tumour stage (vs. stage I), knowledge, self-efficacy, emotional illness representation and social support. Conclusions: Lymphedema self-management behaviours of breast cancer survivors was insufficient. Performance of lymphedema self-management varied with different socio-demographic characteristics, along with different levels of knowledge, self-efficacy, perception and social support. All these identified predictors should be reckoned in assessment and intervention of lymphedema self-management behaviours. Relevance to clinical practice: This study addressed that breast cancer survivors' lymphedema self-management behaviours should be promoted. Focusing on identified predictors, further lymphedema surveillance, knowledge education or social facilitation programs are recommended to enhance their self-management performance and adherence.
The effect of compression therapies and therapeutic modalities on lymphedema secondary to cancer: a rapid review and evidence map

M. L. McNeely,S. M. Shallwani,M. M. Al Onazi,F. Lurie

DOI: https://doi.org/10.1007/s12032-024-02447-w

2024-10-18

Medical Oncology

Abstract:The identification of effective therapeutic modalities to manage lymphedema secondary to cancer is a high priority among patients and clinicians. Complex decongestive therapy (CDT) remains a fundamental intervention for individuals with lymphedema; however, interventions involving modalities such as low level laser therapy, specially designed compression systems, and compression pumps may be helpful to improve outcomes and reduce costs of care. We conducted a rapid review of the literature examining compression therapies and therapeutic modalities in the treatment of lymphedema secondary to cancer. A search of the electronic databases from June 2018 to October 2023 was performed including MEDLINE, EMBASE, and CINAHL. The electronic search yielded 438 potentially relevant citations with 40 randomized controlled trials included in the review, and 30 in the mapping process. Ninety-three percent (n = 37) of the trials included participants with a diagnosis of breast cancer. Across all categories and domains, all but two trials were rated as having 'some concerns' or a 'high risk of bias'. Intervention effects ranged from clinically insignificant to large effects on lymphedema volume. Evidence mapping suggests potential for benefit from (1) compression garments for the prevention of lymphedema, (2) interventions added to CDT in the intensive reduction phase, and (3) nighttime compression and compression pump treatments in the maintenance phase. A multi-centre collaborative research approach is needed to support the conduct of high-quality large-scale trials to inform the optimal type, timing, and combination of compression therapies and therapeutic modalities in the treatment of lymphedema secondary to cancer.

oncology
Features, Predictors, and Treatment of Breast Cancer-related Lymphedema

Xiaochen Zhang,Jill M Oliveri,Electra D Paskett

DOI: https://doi.org/10.1007/s12609-020-00381-0

Abstract:Purpose of review: Breast cancer-related lymphedema (BCRL) is a common sequelae among breast cancer survivors. This review provides updated information on recent studies to prevent, diagnose, and actively treat women with BCRL. Recent findings: In total, 63 articles were identified from 2015 and 2020 that assessed incidence, risk factors, surveillance, measurement and definition, treatment, and awareness of BCRL. Depending on the approach and timing of assessment, BCRL incidence rates ranged from 9.1% to 39%. Modified radical mastectomy, number of positive lymph nodes, and postoperative complications were linked to BCRL risk, in addition to chemotherapy, radiation, axillary lymph node dissection, advanced cancer stage, and higher body mass index. Early detection showed favorable BCRL outcomes (e.g., severity, symptoms). Exercise, self-management, complete decongestive therapy, bandaging, and surgery had positive effects on BCRL outcomes. Summary: Numerous gaps exist within BCRL literature, such as the value of self-reported surveillance options to identify BCRL early, measurement strategies, and definitions of BCRL. In terms of policies, efforts are needed to educate providers, patients, payers, and legislators about the need for consensus to reduce the burden of BCRL in women being treated for breast cancer.
Current evidence on patient precautions for reducing breast cancer-related lymphedema manifestation and progression risks

Julie Hunley,David Doubblestein,Elizabeth Campione

DOI: https://doi.org/10.1007/s12032-024-02408-3

2024-10-18

Medical Oncology

Abstract:Risk management and self-management strategies for breast cancer-related lymphedema (BCRL) must balance best-evidence guidelines and associated risk factor knowledge. There is an evidence-based practice gap in the understanding of whether a change in education about risk factors and whether behavioral changes actually influence BCRL manifestation or progression. The purpose of this study was to (1) review if current evidence supports or refutes patient precautions to prevent the manifestation and/or progression of BCRL, (2) review if behavioral changes result in the prevention or reduction of BCRL, and (3) identify related gaps of knowledge for future research. Evidence map methodology was used to systematically review literature related to reducing the risk of BCRL. Literature searches were conducted in Medline, CINAHL, and Cochrane for the categories of trauma, blood pressure, temperature, air travel, and behavior change. One hundred and forty-eight articles were included for full-text review, of which 37 articles were included in this study. Within the confines of limb and trunk circumferential and/or volume enlargement, a 'just in case' approach to patient education on risk factors may not be appropriate for breast cancer survivors at risk of manifesting lymphedema. Patient education about precautionary risks for the onset of BCRL needs to align with research evidence. There is scant evidence about the risks of BCRL progression suggesting a need for future research.

oncology
Lymphedema following treatment for breast cancer: a new approach to an old problem

Jean O'Toole,Lauren S Jammallo,Melissa N Skolny,Cynthia L Miller,Krista Elliott,Michelle C Specht,Alphonse G Taghian

DOI: https://doi.org/10.1016/j.critrevonc.2013.05.001

Abstract:Lymphedema following treatment for breast cancer can be an irreversible condition with a profound negative impact on quality of life. The lack of consensus regarding standard definitions of clinically significant lymphedema and optimal methods of measurement and quantification are unresolved problems. Inconsistencies persist regarding the appropriate timing of intervention and what forms of treatment should be the standard of care. There are reports that early detection and intervention can prevent progression, however,the Level 1 evidence to support this hypothesis has yet to be generated. To assess these controversies, we propose the implementation of a screening program to detect early lymphedema in conjunction with a randomized, prospective trial designed to generate Level 1 evidence regarding the efficacy of early intervention and appropriate treatment strategies. Collaboration among institutions that manage breast cancer patients is essential to establish a standardized approach to lymphedema and to establish guidelines for best practice.
Evidence-based recommendations regarding risk reduction practices for people at risk of or with breast cancer-related lymphedema: consensus from an expert panel

Cheryl L. Brunelle,Katherine Jackson,Shirin M. Shallwani,Julie H. Hunley,Anna Kennedy,Sarah Fench,Alexandra Hill,Electra D. Paskett,Katrina Rush,Saskia R. J. Thiadens,Joan White,Paula Stewart

DOI: https://doi.org/10.1007/s12032-024-02510-6

2024-10-24

Medical Oncology

Abstract:Several recent studies have investigated the validity of precautionary practices for lymphedema risk reduction after breast cancer treatment, such as avoidance of blood pressure measurements, skin puncture, blood draws, and use of prophylactic compression during air travel. Other studies have elucidated risk factors for breast cancer-related lymphedema, such as axillary lymph node dissection and skin infection (cellulitis). Combining the current evidence base with the consensus opinion of lymphatic experts assembled at the American Cancer Society/Lymphology Association of North America Summit in October 2023, updated evidence-based risk reduction recommendations are presented for those with or at risk of breast cancer-related lymphedema. Recommendation topics include prospective surveillance, patient education, individual risk factors, exercise, blood pressure, skin care and hygiene, skin puncture and blood draws, surgical procedures, prophylactic compression, air travel, and hot climate and sauna. These recommendations will help inform education and medical choices for individuals treated for breast cancer who are at risk of or diagnosed with breast cancer-related lymphedema. More high-quality evidence is required to allow the development of risk reduction recommendations for other cancer types such as gynecological, melanoma, and head and neck. It is recommended that clinicians and organizations serving people at risk of or with lymphedema align risk reduction guidelines with the evidence-based recommendations provided within this consensus document and companion manuscripts from the American Cancer Society/Lymphology Association of North America Lymphedema Summit: Forward Momentum: Future Steps in Lymphedema Management.

oncology

P300 Sequence Effects, Probability, and Interstimulus Interval

Consensus statement on non-cancer-related risk factors for development of secondary lymphedema

Cancer-Related Lymphedema Risk Factors, Diagnosis, Treatment, and Impact: A Review

Breast cancer‐related lymphedema: A comprehensive analysis of risk factors

Prevalence and incidence of cancer related lymphedema in low and middle-income countries: a systematic review and meta-analysis

Policy Forum : Confusion Worse Confounded — The Supreme Court ’ s GAAR Decisions

Chemical reaction kinetics is back: Attempts to deal with complexity in biology: Developing a quantitative molecular view to understanding life

Risk Factors for Breast Cancer-Related Lymphedema: An Umbrella Review

Risk Factors Associated with Breast Cancer-Related Lymphedema: A Systematic Review and Meta-Analysis

The role of information sources and objective risk status on lymphedema risk-minimization behaviors in women recently diagnosed with breast cancer

Risk factors of breast cancer-related lymphoedema: protocol of an umbrella review

Advances in understanding and management of lymphoedema (cancer, primary)

Psychosocial Impact of Living With Cancer-Related Lymphedema

Liposomal vincristine for the treatment of human acute lymphoblastic leukaemia in severe combined immunodeficient (SCID) mice.

The Impact of Obesity on Success of Immediate Lymphatic Reconstruction for Prevention of Breast Cancer-Related Lymphedema

Factors associated with lymphedema self-management behaviours among breast cancer survivors: A cross-sectional study

The effect of compression therapies and therapeutic modalities on lymphedema secondary to cancer: a rapid review and evidence map

Features, Predictors, and Treatment of Breast Cancer-related Lymphedema

Current evidence on patient precautions for reducing breast cancer-related lymphedema manifestation and progression risks

Lymphedema following treatment for breast cancer: a new approach to an old problem

Evidence-based recommendations regarding risk reduction practices for people at risk of or with breast cancer-related lymphedema: consensus from an expert panel